Close Menu

NEW YORK (GenomeWeb) – Roche today announced the CE-IVD marking of its Cobas MTB-RIF/INH test that detects mutations associated with resistance to the antibiotics rifampicin and isoniazid within tuberculosis DNA.

The assay is part of Roche's mycobacteria test menu that runs on its Cobas 6800/8800 automated molecular platforms and also includes the Cobas MTB and Cobas MAI tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.